Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q3 FY2026 Earnings Presentation
37 slides from Jubilant Ingrevia's earnings presentation, Feb 5, 2026
Slide 1: Stock exchange cover letter
February 05, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P.J. Tower Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E) Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Press Release and presentation on the financials and oper
Slide 2: Press Release: Q3'FY26 Results
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Thursday, February 05th, 2026 JUBILANT INGREVIA LIMITED – Q3’FY26 RESULTS Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y Total Revenue 1,057 1,1
Slide 3: Press release: market update and future outlook
In the Nutrition market, Niacinamide demand remains strong across key segments including Feed, Food, and Cosmetics. Pricing, however, has been under strain due to supply–demand mismatches, though we anticipate margins to improve marginally in the next quarter. Meanwhile, demand for Choline (Vitamin
Slide 4: Business update
3) In our Nutrition and Health Solutions business, we delivered volume growth both quarter-on-quarter and year-on-year. Demand for feed-grade Vitamin B3 remained steady, with volumes reaching their highest level in the past seven quarters. While intensified global competition placed some pressure on
Slide 5: Q3'FY26 Highlights | Segment Wise Analysis
Q3’FY26 Highlights | Segment Wise Analysis A. Specialty Chemicals Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y Segment Revenue 468 485 458 -6% -2% 1,331 1,421 7% % Share of Overall Revenue 44% 43% 44% 43% 44% EBITDA 121 125 116 -8% -4% 293 371 27% % EBITDA Margin 26% 26% 25
Slide 6: Nutrition & Health Solutions; Chemical Intermediates
B. Nutrition & Health Solutions 1 Particulars Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y Segment Revenue 190 181 201 11% 6% 558 560 0% % Share of Overall Revenue 18% 16% 19% 18% 17% EBITDA 25 21 23 7% -10% 72 68 -6% % EBITDA Margin 13% 12% 11% 13% 12% % Contribution to EBITDA 2 15% 13
Slide 7: Income Statement – Q3'FY26
Price - Segment realization were lower on YoY basis - Prices remained subdued, although expected to rise with increasing raw material costs Business Drivers - QoQ revenue declined driven by lower realization across key products: Acetic Anhydride and Ethyl Acetate, also because of lower volumes due t
Slide 8: Segment P&L and Debt Position
4. Segment P&L – Q3’FY26 Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 QoQ (%) YoY (%) 9M'FY25 9M'FY26 YoY (%) Revenue Speciality Chemicals 468 485 458 (6%) (2%) 1,331 1,421 7% Nutrition & Health Solutions 190 181 201 11% 6% 558 560 0% Chemical Intermediates 400 455 393 (14%) (2%) 1,237 1,229 (1%) Total Reve
Slide 9: For more information, please contact
For more information, please contact: For Investors Pavleen Taneja Siddharth Rangnekar Jubilant Ingrevia Limited CDR India Ph: +91-120 436 1000 Ph: +91 22 6645 1209 E-mail: pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media Sandipan Ghatak Sahir Seth Ph: +919810776182 M: +91 999927011
Slide 10: Investor Presentation
Investor Presentation February 2026 Innovating for a Sustainable Future 1
Slide 11: Forward-looking statements disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 12: Management commentary on results
“We are pleased to share the financial results for the third quarter and nine months of this fiscal year. On a year to date basis, our Speciality Chemicals segment has continued to fuel growth momentum, delivering revenue expansion and a robust double-digit increase in EBITDA. Our Nutrition business
Slide 13: Business Update
Business Update: The Specialty Chemicals segment continued on its revenue growth trajectory on year to date basis and continued to report and maintain 26%+ margins during the YTD period, driven primarily by strong volume traction from Fine Chemicals and Pyridine. I am pleased to share that our CDMO
Slide 14: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Q3’FY26 Highlights 1 9 Business Segments Update 5
Slide 15: Company Overview
WV J UBILANT INGREVIA Company Overview. ° hh ds)
Slide 16: Transformation into Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine derivatives • Started as VAM • Forward integration into • Foray into Diketene derivatives • Foray into Pyridine Organics Pyridine deriv
Slide 17: Business segments
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 18: Revenue mix by segment and geography
Consumer ROW Nutrition 4% 12% & Health Agro North Solutions 20% Pharma America 8% 17% Specialty 34% India Chemicals 56% 44% Europe Chemical Industrial 24% Intermediates 23% 38% Nutrition 19% 9
Slide 19: Manufacturing facilities and capabilities
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 20: R&D Centers
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 ~150 ~30 R&D Centers Scientists PhDs 11
Slide 21: Leadership team
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola President, Chief Preside
Slide 22: Q3'FY26 Highlights
Ww a ° at UBILANT —_" J INGREVIA + vas “en 8A ww . Q3°FY26 Highlights -
Slide 23: Pharma, Agrochem and Nutrition market update
PHARMA • Volumes continued to remain steady across segments, especially in our core products in Fine Chemicals • US market remains cautious with customers adopting a wait and watch approach amidst Tariff and Geopolitical uncertainty • Paracetamol market continued to recover with moderate growth AGRO
Slide 24: Customer, business, operations and ESG highlights
Business Customer Operations / ESG • Specialty: Continued traction with • KAM: 100+ molecules with 3500Crs+ • Green power impact continued in Q3: CDMO customers; Volume growth potential O2 Power in Bharuch; (Renewable across Pyridine portfolio power share: ~34% vs 28% in Q2) • Confirmed: ~16+ molecu
Slide 25: Revenue & EBITDA during the quarter
Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y Total Revenue 1,057 1,121 1,051 -6% -1% 3,126 3,210 3% Total EBITDA 148 146 136 -7% -8% 402 436 8% EBITDA Margin (%) 14% 13% 13% 13% 14% PAT before Exceptional Items 69 69 60 -14% -14% 177 205 15% PAT Margin(%) before Exceptional
Slide 26: Segment-wise EBITDA Share (%)
Segment-wise EBITDA Share (%) 6% 13% 10% 12% 12% 25% 27% 17% 36% 36% 14% 13% 12% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 76% 75% 76% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY
Slide 27: Segment EBITDA and margins
Specialty Chemicals Nutrition Chemical Intermediates EBITDA (INR Crs) EBITDA (INR Crs) EBITDA (INR Crs) Y.o.Y Growth -4% Y.o.Y De-Growth -10% Y.o.Y Growth -31% Q.o.Q De-Growth -7% Q.o.Q De-Growth 7% Q.o.Q Growth -24% 121 125 116 25 23 21 22 20 26% 26% 25% 13% 15 12% 11% 5% 4% 4% Q3 FY25 Q2 FY26 Q3 F
Slide 28: Business Segments Overview
Business Segments Overview 19
Slide 29: Specialty Chemicals: Pharma, Agrochemical, CDMO/FC
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Pharma End-use demand remained stable across both YoY and QoQ basis 1 Particulars Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y - Pricing remained muted Segment Revenue 468 485 458 -6% -2% 1,331 1,421 7% Pharma - US: Customers remain cautious am
Slide 30: Nutrition & Health Solutions: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Market demand remained steady; Recorded highest ever volumes in last 7 Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y quarters; Segment Revenue 190 181 201 11% 6% 558 560 0% - Competition volume push weighed on Feed B3 global prices
Slide 31: Chemical Intermediates
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Increase in India market volumes with Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 Q-o-Q Y-o-Y 9M'FY25 9M'FY26 Y-o-Y marginal uptick in agro and paracetamol Segment Revenue 400 455 393 -14% -2% 1,237 1,229 -1% - Continued market challenges in Europe, % Share of Ove
Slide 32: Annexures
w eee ar Devene lA
Slide 33: Income Statement
Particulars1 Q3'FY25 Q2'FY26 Q3'FY26 QoQ YoY 9M'FY25 9M'FY26 YoY Revenue from operations a) Sales/Income from operations 1046 1110 1040 -6% -1% 3086 3179 3% b) Other operating income 11 11 11 2% 5% 41 31 -24% Total revenue from operations 1057 1121 1051 -6% -1% 3126 3210 3% Other income 9 11 9 -13%
Slide 34: Segment P&L
1 Particulars Q3'FY25 Q2'FY26 Q3'FY26 QoQ (%) YoY (%) 9M'FY25 9M'FY26 YoY (%) Revenue Speciality Chemicals 468 485 458 (6%) (2%) 1,331 1,421 7% Nutrition & Health Solutions 190 181 201 11% 6% 558 560 0% Chemical Intermediates 400 455 393 (14%) (2%) 1,237 1,229 (1%) Total Revenue from Operations 1,05
Slide 35: Debt Position as on 31 December 2025
Particulars1 31-Dec-24 30-Jun-25 30-Sep-25 31-Dec-25 Long Term Borrowings 457 448 458 452 Short Term Borrowings 291 360 336 268 Total Gross Debt 748 808 794 720 Cash & Equivalent 67 107 47 176 Total Net Debt 681 700 748 544 YoY change -20% • Capital expenditure for the quarter stood at ₹265 crore, p
Slide 36: Earnings call details
Date : February 05th, 2026 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on t
Slide 37: Thank you for your time
Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, For Investors: Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to Pavleen Taneja glo